20:04 , Apr 25, 2019 |  BC Innovations  |  Finance

The academic founders' conundrum

First-time academic entrepreneurs face a circular problem: while they’re continually sought after by VCs and pharmas seeking the next “big thing”, they also face an arduous path to establish their bona fides - not for...
19:14 , Nov 16, 2018 |  BC Week In Review  |  Financial News

V-Bio, Gimv lead €37M Camel-IDS series A

Camelid-derived antibody company Camel-IDS N.V. (Brussels, Belgium) raised €37 million ($41.7 million) in a series A round Nov. 15 to support Phase II trials of lead brain metastatic breast cancer candidate, CAM-H2. V-Bio Ventures and...
00:13 , Nov 16, 2018 |  BC Extra  |  Financial News

V-Bio, Gimv lead €37M Camel-IDS series A

Camelid-derived antibody company Camel-IDS N.V. (Brussels, Belgium) raised €37 million ($41.7 million) in a series A round to support Phase II trials of lead brain metastatic breast cancer candidate, CAM-H2. V-Bio Ventures and Gimv led...
23:58 , Sep 25, 2017 |  BC Extra  |  Company News

Management tracks: TapImmune, Camel-IDS, Arvinas

Immuno-oncology company TapImmune Inc. (NASDAQ:TPIV) named Peter Hoang president and CEO. He was SVP of business development and strategy at Bellicum Pharmaceuticals Inc. (NASDAQ:BLCM). Cancer company Camel-IDS N.V. (Brussels, Belgium) named Ruth Devenyns CEO, a...